MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
SCYNEXIS Long-Term Debt 2011-2025 | SCYX
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt SCYNEXIS
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.58 M | 2.92 M | 34.4 M | 16.5 M | 11.5 M | 15.1 M | 10.3 M | 14.3 M | - | - | - | 15 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 34.4 M | 2.58 M | 13.6 M |
Quarterly Long-Term Debt SCYNEXIS
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.82 M | 1.94 M | 2.06 M | 2.18 M | 2.28 M | 2.39 M | 2.49 M | 2.58 M | 2.67 M | 2.76 M | 34.6 M | 2.92 M | 34.2 M | 33.9 M | 33.7 M | 3.2 M | 28.6 M | 28.4 M | 3.22 M | 3.27 M | 3.27 M | 3.27 M | 3.27 M | - | - | - | - | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.6 M | 1.82 M | 11.4 M |
Long-Term Debt of other stocks in the Drug manufacturers industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
256 K | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
38.5 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
21.8 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
300 M | $ 1.69 | -3.13 % | $ 182 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
5.01 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
4.27 M | $ 3.06 | -6.57 % | $ 1.61 B | Canada |
 |
Agile Therapeutics
AGRX
|
1.52 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
295 M | $ 5.18 | -4.17 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
4.86 B | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
24.1 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
29 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
16.7 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
56.2 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
8.15 B | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
446 M | $ 11.76 | 2.98 % | $ 602 M | USA |
 |
Evoke Pharma
EVOK
|
5 M | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
93 K | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.12 M | $ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
122 M | $ 7.17 | 1.85 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
247 M | $ 46.47 | -1.25 % | $ 1.52 B | USA |
 |
China Pharma Holdings
CPHI
|
39.9 K | $ 1.55 | -0.64 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
21.9 B | $ 6.83 | -1.37 % | $ 2.49 B | Canada |
 |
Lannett Company
LCI
|
615 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
718 K | $ 4.86 | 0.73 % | $ 640 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.82 | -5.36 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
4.94 M | $ 3.03 | 19.57 % | $ 42.6 M | USA |
 |
Pacira BioSciences
PCRX
|
585 M | $ 26.71 | 1.6 % | $ 1.24 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
65 K | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
8.29 M | $ 0.88 | -5.09 % | $ 20.5 M | USA |
 |
Solid Biosciences
SLDB
|
1.23 M | $ 5.81 | -1.02 % | $ 237 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
27 K | $ 3.45 | -3.96 % | $ 4.28 M | USA |
 |
PetIQ
PETQ
|
438 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 4.32 | 6.4 % | $ 130 M | USA |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
3.58 B | $ 12.85 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
2.4 M | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
315 K | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
339 K | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
16.2 M | $ 2.02 | -8.68 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
611 K | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
2.92 M | $ 2.43 | 0.41 % | $ 328 M | USA |
 |
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
2.4 M | $ 1.4 | 14.75 % | $ 6.04 M | USA |
 |
Tricida
TCDA
|
11.3 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
221 M | $ 11.41 | -6.09 % | $ 7.05 B | Canada |
 |
TherapeuticsMD
TXMD
|
6.53 M | $ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
1.81 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
18 B | $ 11.68 | 0.21 % | $ 14.2 B | USA |